TRANSCODE THERAPEUTICS INC (RNAZ)

Company Profile

Transcode Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2021-04-28. TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Its preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. The company also has two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment, and TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells, as well as TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines that are designed to activate cytotoxic immune responses.

Company Info

TRANSCODE THERAPEUTICS INC

6 Liberty Square, #2382

Boston MASSACHUSETTS

P: 18573016857

CEO: Robert Michael Dudley

Employees: 19

Website: https://www.transcodetherapeutics.com/